Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 2
2005 1
2006 2
2008 2
2009 1
2013 4
2014 1
2015 1
2016 4
2017 4
2018 3
2019 5
2020 4
2021 3
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Protein C deficiency as the major cause of thrombophilias in childhood.
Ohga S, Ishiguro A, Takahashi Y, Shima M, Taki M, Kaneko M, Fukushima K, Kang D, Hara T; Japan Childhood Thrombophilia Study Group. Ohga S, et al. Among authors: taki m. Pediatr Int. 2013 Jun;55(3):267-71. doi: 10.1111/ped.12102. Pediatr Int. 2013. PMID: 23521084 Review.
Pediatric thromboembolism: a national survey in Japan.
Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, Shima M. Ishiguro A, et al. Among authors: taki m. Int J Hematol. 2017 Jan;105(1):52-58. doi: 10.1007/s12185-016-2079-y. Epub 2016 Aug 18. Int J Hematol. 2017. PMID: 27539155
The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs.
Kashiwakura Y, Baatartsogt N, Yamazaki S, Nagao A, Amano K, Suzuki N, Matsushita T, Sawada A, Higasa S, Yamasaki N, Fujii T, Ogura T, Takedani H, Taki M, Matsumoto T, Yamanouchi J, Sakai M, Nishikawa M, Yatomi Y, Yada K, Nogami K, Watano R, Hiramoto T, Hayakawa M, Kamoshita N, Kume A, Mizukami H, Ishikawa S, Sakata Y, Ohmori T. Kashiwakura Y, et al. Among authors: taki m. Mol Ther Methods Clin Dev. 2022 Oct 27;27:404-414. doi: 10.1016/j.omtm.2022.10.014. eCollection 2022 Dec 8. Mol Ther Methods Clin Dev. 2022. PMID: 36381300 Free PMC article.
Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
Ogiwara K, Taki M, Suzuki T, Takedani H, Matsushita T, Amano K, Matsumoto M, Nishio K, Shima M, Kasahara M, Nogami K. Ogiwara K, et al. Among authors: taki m. BMJ Open. 2022 Feb 17;12(2):e056922. doi: 10.1136/bmjopen-2021-056922. BMJ Open. 2022. PMID: 35177463 Free PMC article. Clinical Trial.
AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study.
Shima M, Takedani H, Kitsukawa K, Taki M, Ishiguro A, Nagao A, Yamaguchi-Suita H, Kyogoku Y, Yoshida S, Nogami K. Shima M, et al. Among authors: taki m. BMJ Open. 2022 Jun 13;12(6):e059667. doi: 10.1136/bmjopen-2021-059667. BMJ Open. 2022. PMID: 35697445 Free PMC article.
Clinical and pathophysiological delineation of musculocontractural Ehlers-Danlos syndrome caused by dermatan sulfate epimerase deficiency (mcEDS-DSE): A detailed and comprehensive glycobiological and pathological investigation in a novel patient.
Minatogawa M, Hirose T, Mizumoto S, Yamaguchi T, Nagae C, Taki M, Yamada S, Watanabe T, Kosho T. Minatogawa M, et al. Among authors: taki m. Hum Mutat. 2022 Dec;43(12):1829-1836. doi: 10.1002/humu.24437. Epub 2022 Jul 23. Hum Mutat. 2022. PMID: 35842784
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M, Hanabusa H, Taki M, Matsushita T, Sato T, Fukutake K, Fukazawa N, Yoneyama K, Yoshida H, Nogami K. Shima M, et al. Among authors: taki m. N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769. N Engl J Med. 2016. PMID: 27223146 Free article. Clinical Trial.
Clinical conditions and risk factors for inhibitor-development in patients with haemophilia: A decade-long prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2).
Nogami K, Taki M, Matsushita T, Kojima T, Oka T, Ohga S, Kawakami K, Sakai M, Suzuki T, Higasa S, Horikoshi Y, Shinozawa K, Tamura S, Yada K, Imaizumi M, Ohtsuka Y, Iwasaki F, Kobayashi M, Takamatsu J, Takedani H, Nakadate H, Matsuo Y, Matsumoto T, Fujii T, Fukutake K, Shirahata A, Yoshioka A, Shima M; J-HIS2 study group. Nogami K, et al. Among authors: taki m. Haemophilia. 2022 Sep;28(5):745-759. doi: 10.1111/hae.14602. Epub 2022 Jun 11. Haemophilia. 2022. PMID: 35689832
43 results